Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase II Trial of Mutation-Targeted Therapy with Sunitinib or Everolimus in Patients with Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas with or without Cytoreductive Surgery

Summary

The purpose of this phase II trial is to see if drugs selected based on the defective gene result in better tumor response. The drugs are sunitinib and everolimus. Biomarker testing must be completed during screening for the trial; prior reports are not acceptable.

General Information

NCT#: NCT02315625
Study ID: 15-C-0040 or 150040
Trial Phase: Phase II

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Everolimus, Sunitinib, Surgery

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search